191 related articles for article (PubMed ID: 19563872)
21. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin.
Li C; Zhang D; Guo H; Hao L; Zheng D; Liu G; Shen J; Tian X; Zhang Q
Int J Pharm; 2013 May; 448(1):79-86. PubMed ID: 23518367
[TBL] [Abstract][Full Text] [Related]
22. Anticancer activity of an essential oil from Cymbopogon flexuosus.
Sharma PR; Mondhe DM; Muthiah S; Pal HC; Shahi AK; Saxena AK; Qazi GN
Chem Biol Interact; 2009 May; 179(2-3):160-8. PubMed ID: 19121295
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension.
Du S; Zhu L; Du B; Shi X; Zhang Z; Wang S; Zhang C
Drug Dev Ind Pharm; 2012 Apr; 38(4):431-8. PubMed ID: 21951208
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.
Jia L; Shen J; Zhang D; Duan C; Liu G; Zheng D; Tian X; Liu Y; Zhang Q
Int J Biol Macromol; 2012 Apr; 50(3):523-9. PubMed ID: 22301003
[TBL] [Abstract][Full Text] [Related]
25. Anticancer effects of oridonin on colon cancer are mediated via BMP7/p38 MAPK/p53 signaling.
Liu RX; Ma Y; Hu XL; Ren WY; Liao YP; Wang H; Zhu JH; Wu K; He BC; Sun WJ
Int J Oncol; 2018 Nov; 53(5):2091-2101. PubMed ID: 30132514
[TBL] [Abstract][Full Text] [Related]
26. Novel galactosylated biodegradable nanoparticles for hepatocyte-delivery of oridonin.
Wang Y; Liu X; Liu G; Guo H; Li C; Zhang Y; Zhang F; Zhao Z; Cheng H
Int J Pharm; 2016 Apr; 502(1-2):47-60. PubMed ID: 26911417
[TBL] [Abstract][Full Text] [Related]
27. Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin.
Duan C; Gao J; Zhang D; Jia L; Liu Y; Zheng D; Liu G; Tian X; Wang F; Zhang Q
Biomacromolecules; 2011 Dec; 12(12):4335-43. PubMed ID: 22077387
[TBL] [Abstract][Full Text] [Related]
28. [Study on stability of oridonin solution].
Xu J; Zhao J; Wang J; Feng N; Tan R; Liu Y
Zhongguo Zhong Yao Za Zhi; 2009 Jan; 34(1):47-9. PubMed ID: 19382449
[TBL] [Abstract][Full Text] [Related]
29. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat.
Rabinow B; Kipp J; Papadopoulos P; Wong J; Glosson J; Gass J; Sun CS; Wielgos T; White R; Cook C; Barker K; Wood K
Int J Pharm; 2007 Jul; 339(1-2):251-60. PubMed ID: 17398045
[TBL] [Abstract][Full Text] [Related]
30. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.
Zhou X; Zhang X; Ye Y; Zhang T; Wang H; Ma Z; Wu B
Int J Pharm; 2015 Feb; 479(2):391-8. PubMed ID: 25556104
[TBL] [Abstract][Full Text] [Related]
31. Chitosan-g-poly(N-isopropylacrylamide) based nanogels for tumor extracellular targeting.
Duan C; Zhang D; Wang F; Zheng D; Jia L; Feng F; Liu Y; Wang Y; Tian K; Wang F; Zhang Q
Int J Pharm; 2011 May; 409(1-2):252-9. PubMed ID: 21356283
[TBL] [Abstract][Full Text] [Related]
32. Oridonin inhibits the proliferation of human colon cancer cells by upregulating BMP7 to activate p38 MAPK.
Ren CM; Li Y; Chen QZ; Zeng YH; Shao Y; Wu QX; Yuan SX; Yang JQ; Yu Y; Wu K; He BC; Sun WJ
Oncol Rep; 2016 May; 35(5):2691-8. PubMed ID: 26986967
[TBL] [Abstract][Full Text] [Related]
33. RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin.
Xu J; Zhao JH; Liu Y; Feng NP; Zhang YT
Int J Nanomedicine; 2012; 7():211-9. PubMed ID: 22275836
[TBL] [Abstract][Full Text] [Related]
34. Galactosylated bovine serum albumin nanoparticles for parenteral delivery of oridonin: tissue distribution and pharmacokinetic studies.
Li C; Zhang D; Guo Y; Guo H; Li T; Hao L; Zheng D; Liu G; Zhang Q
J Microencapsul; 2014; 31(6):573-8. PubMed ID: 24697186
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic ent-kaurane diterpenoids from Isodon henryi.
Zhao Y; Huang SX; Yang LB; Pu JX; Xiao WL; Li LM; Lei C; Weng ZY; Han QB; Sun HD
Planta Med; 2009 Jan; 75(1):65-9. PubMed ID: 19031362
[TBL] [Abstract][Full Text] [Related]
36. Tissue distribution of 2-methoxyestradiol nanosuspension in rats and its antitumor activity in C57BL/6 mice bearing lewis lung carcinoma.
Shen G; Wang Q; Zhang Q; Sun H; Zhao Y; Zhang Z; Du B
Drug Deliv; 2012; 19(7):327-33. PubMed ID: 22985261
[TBL] [Abstract][Full Text] [Related]
37. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.
Wang Y; Liu Z; Zhang D; Gao X; Zhang X; Duan C; Jia L; Feng F; Huang Y; Shen Y; Zhang Q
Colloids Surf B Biointerfaces; 2011 Apr; 83(2):189-97. PubMed ID: 21176876
[TBL] [Abstract][Full Text] [Related]
38. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin.
Zhang P; Liu Y; Feng N; Xu J
Int J Pharm; 2008 May; 355(1-2):269-76. PubMed ID: 18242895
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine.
Bezerra DP; de Castro FO; Alves AP; Pessoa C; de Moraes MO; Silveira ER; Lima MA; Elmiro FJ; de Alencar NM; Mesquita RO; Lima MW; Costa-Lotufo LV
J Appl Toxicol; 2008 Mar; 28(2):156-63. PubMed ID: 17541943
[TBL] [Abstract][Full Text] [Related]
40. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Patil Y; Sadhukha T; Ma L; Panyam J
J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
